A cathepsinek és a plasminogen activator/inhibitor rendszer viselkedése colorectalis carcinomában.

Translated title of the contribution: The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer

L. Herszényi, F. Farinati, M. Plebani, G. István, Z. Sápi, P. Carraro, M. De Paoli, R. Naccarato, Z. Tulassay

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cysteine proteases [Cathepsin B and L (CATB, CATL)] and the serine protease urokinase type plasminogen activator (UPA) with its inhibitor type-1 (PAI-1) are thought to play an important part in colorectal cancer invasion and metastasis. To our knowledge, however, cathepsins and plasminogen activator/inhibitor system have not been evaluated in the same study. The authors using the ELISA method, determined the protease antigen concentrations in colorectal cancer tissue and in normal tissue distant from tumour, in 35 patients with colorectal cancer. They also evaluated the relationship that these proteases may have with the major histomorphological parameters and tumour staging. Significantly higher antigen levels were found: 1. in cancerous tissue vs. tumour free tissue (CATB, CATL, UPA, PAI-1); in colorectal cancer with vs. without metastasis (CATB, CATL, UPA, PAI-1); 3. in poorly vs. well differentiated tumours (CATB, UPA, PAI-1); 4. in advanced Dukes' stages (CATB, UPA, PAI-1). The simultaneous activation of cathepsins and plasminogen activator/inhibitor system in colorectal cancer confirms their role in colorectal tumor biology and particularly in the process of invasion and metastasis. Our results suggest the possible prognostic impact of these proteases in colorectal cancer.

Original languageHungarian
Pages (from-to)1833-1836
Number of pages4
JournalOrvosi Hetilap
Volume140
Issue number33
Publication statusPublished - Aug 15 1999

Fingerprint

Plasminogen Inactivators
Cathepsins
Colorectal Neoplasms
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Peptide Hydrolases
Neoplasm Metastasis
Cathepsin L
Antigens
Neoplasms
Cathepsin B
Cysteine Proteases
Neoplasm Staging
Serine Proteases
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A cathepsinek és a plasminogen activator/inhibitor rendszer viselkedése colorectalis carcinomában. / Herszényi, L.; Farinati, F.; Plebani, M.; István, G.; Sápi, Z.; Carraro, P.; De Paoli, M.; Naccarato, R.; Tulassay, Z.

In: Orvosi Hetilap, Vol. 140, No. 33, 15.08.1999, p. 1833-1836.

Research output: Contribution to journalArticle

Herszényi, L, Farinati, F, Plebani, M, István, G, Sápi, Z, Carraro, P, De Paoli, M, Naccarato, R & Tulassay, Z 1999, 'A cathepsinek és a plasminogen activator/inhibitor rendszer viselkedése colorectalis carcinomában.', Orvosi Hetilap, vol. 140, no. 33, pp. 1833-1836.
Herszényi, L. ; Farinati, F. ; Plebani, M. ; István, G. ; Sápi, Z. ; Carraro, P. ; De Paoli, M. ; Naccarato, R. ; Tulassay, Z. / A cathepsinek és a plasminogen activator/inhibitor rendszer viselkedése colorectalis carcinomában. In: Orvosi Hetilap. 1999 ; Vol. 140, No. 33. pp. 1833-1836.
@article{21d46d6e8794489b939cb74e10017132,
title = "A cathepsinek {\'e}s a plasminogen activator/inhibitor rendszer viselked{\'e}se colorectalis carcinom{\'a}ban.",
abstract = "Cysteine proteases [Cathepsin B and L (CATB, CATL)] and the serine protease urokinase type plasminogen activator (UPA) with its inhibitor type-1 (PAI-1) are thought to play an important part in colorectal cancer invasion and metastasis. To our knowledge, however, cathepsins and plasminogen activator/inhibitor system have not been evaluated in the same study. The authors using the ELISA method, determined the protease antigen concentrations in colorectal cancer tissue and in normal tissue distant from tumour, in 35 patients with colorectal cancer. They also evaluated the relationship that these proteases may have with the major histomorphological parameters and tumour staging. Significantly higher antigen levels were found: 1. in cancerous tissue vs. tumour free tissue (CATB, CATL, UPA, PAI-1); in colorectal cancer with vs. without metastasis (CATB, CATL, UPA, PAI-1); 3. in poorly vs. well differentiated tumours (CATB, UPA, PAI-1); 4. in advanced Dukes' stages (CATB, UPA, PAI-1). The simultaneous activation of cathepsins and plasminogen activator/inhibitor system in colorectal cancer confirms their role in colorectal tumor biology and particularly in the process of invasion and metastasis. Our results suggest the possible prognostic impact of these proteases in colorectal cancer.",
author = "L. Hersz{\'e}nyi and F. Farinati and M. Plebani and G. Istv{\'a}n and Z. S{\'a}pi and P. Carraro and {De Paoli}, M. and R. Naccarato and Z. Tulassay",
year = "1999",
month = "8",
day = "15",
language = "Hungarian",
volume = "140",
pages = "1833--1836",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - A cathepsinek és a plasminogen activator/inhibitor rendszer viselkedése colorectalis carcinomában.

AU - Herszényi, L.

AU - Farinati, F.

AU - Plebani, M.

AU - István, G.

AU - Sápi, Z.

AU - Carraro, P.

AU - De Paoli, M.

AU - Naccarato, R.

AU - Tulassay, Z.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - Cysteine proteases [Cathepsin B and L (CATB, CATL)] and the serine protease urokinase type plasminogen activator (UPA) with its inhibitor type-1 (PAI-1) are thought to play an important part in colorectal cancer invasion and metastasis. To our knowledge, however, cathepsins and plasminogen activator/inhibitor system have not been evaluated in the same study. The authors using the ELISA method, determined the protease antigen concentrations in colorectal cancer tissue and in normal tissue distant from tumour, in 35 patients with colorectal cancer. They also evaluated the relationship that these proteases may have with the major histomorphological parameters and tumour staging. Significantly higher antigen levels were found: 1. in cancerous tissue vs. tumour free tissue (CATB, CATL, UPA, PAI-1); in colorectal cancer with vs. without metastasis (CATB, CATL, UPA, PAI-1); 3. in poorly vs. well differentiated tumours (CATB, UPA, PAI-1); 4. in advanced Dukes' stages (CATB, UPA, PAI-1). The simultaneous activation of cathepsins and plasminogen activator/inhibitor system in colorectal cancer confirms their role in colorectal tumor biology and particularly in the process of invasion and metastasis. Our results suggest the possible prognostic impact of these proteases in colorectal cancer.

AB - Cysteine proteases [Cathepsin B and L (CATB, CATL)] and the serine protease urokinase type plasminogen activator (UPA) with its inhibitor type-1 (PAI-1) are thought to play an important part in colorectal cancer invasion and metastasis. To our knowledge, however, cathepsins and plasminogen activator/inhibitor system have not been evaluated in the same study. The authors using the ELISA method, determined the protease antigen concentrations in colorectal cancer tissue and in normal tissue distant from tumour, in 35 patients with colorectal cancer. They also evaluated the relationship that these proteases may have with the major histomorphological parameters and tumour staging. Significantly higher antigen levels were found: 1. in cancerous tissue vs. tumour free tissue (CATB, CATL, UPA, PAI-1); in colorectal cancer with vs. without metastasis (CATB, CATL, UPA, PAI-1); 3. in poorly vs. well differentiated tumours (CATB, UPA, PAI-1); 4. in advanced Dukes' stages (CATB, UPA, PAI-1). The simultaneous activation of cathepsins and plasminogen activator/inhibitor system in colorectal cancer confirms their role in colorectal tumor biology and particularly in the process of invasion and metastasis. Our results suggest the possible prognostic impact of these proteases in colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033566426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033566426&partnerID=8YFLogxK

M3 - Article

C2 - 10489782

AN - SCOPUS:0033566426

VL - 140

SP - 1833

EP - 1836

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -